Skip to content
The Policy VaultThe Policy Vault

Symlin (pramlintide subcutaneous injection – AstraZeneca) — Cigna

Diabetes Mellitus, Type 2

Initial criteria

  • Medication is prescribed in adjunct to insulin therapy

Approval duration

1 year